Search the Newsreel

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

Citizens Jmp has reduced its price target for Spruce Biosciences (NASDAQ:SPRB) to $144.00 from $150.00 but maintained a "market outperform" rating, indicating a potential upside of nearly 199%. Despite a wider-than-expected quarterly loss of $6.68 per share, analyst sentiment remains largely positive with a …

Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com

Citizens has lowered its price target for Spruce Biosciences (NASDAQ:SPRB) from $150.00 to $144.00, citing potential share dilution, while maintaining a Market Outperform rating. Despite the reduction, the new target still indicates significant upside, although InvestingPro data suggests the stock may be overvalued at …

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences announced its second-quarter 2026 financial results and provided updates on its TA-ERT program for MPS IIIB. The company anticipates submitting a Biologics License Application (BLA) in Q4 2026 and initiating the TrAnsform confirmatory study and an Expanded Access Program (EAP) around the …

Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS

Spruce Biosciences (NASDAQ:SPRB) reported a quarterly loss of $6.68 per share, missing the consensus estimate of a $5.79 loss by $0.89. Despite the earnings miss, shares remained flat, and analysts maintain a "Moderate Buy" rating with an average price target of $162.62. The company …

SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary

Spruce Biosciences, Inc. (SPRB) reported a significantly widened net loss of $(16.2M) in 2Q 2026, compared to $(2.1M) in 2Q 2025, with diluted loss per share increasing to $(6.68). The company did not report revenue but highlighted regulatory progress with TA-ERT receiving FDA Breakthrough …

Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M

Spruce Biosciences (SPRB) reported an increased net loss of $28.5 million for the first half of 2026, up from $16.1 million in 2025, primarily due to higher research and development expenses for its lead asset, tralesinidase alfa (TA-ERT). Despite increased spending, the company significantly …

Spruce Biosciences (SPRB) doubles cash as TA-ERT BLA and $5.5M backing advance

Spruce Biosciences GAAP EPS of -$6.68

* Spruce Biosciences press release [https://seekingalpha.com/pr/20616630-spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SPRB [https://seekingalpha.com/symbol/SPRB]): Q2 GAAP EPS of -$6.68. * Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025. * Spruce believes that its cash and cash equivalents …

Spruce Biosciences: Q4 Biologics Filing Anticipated; Child Study Expected

Spruce Biosciences receives $5.5M from patient advocacy groups

Spruce Biosciences (NASDAQ:SPRB) has secured a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society. This funding will partially support an expanded access program for its investigational therapy, tralesinidase alfa enzyme replacement therapy (TA-ERT), aimed at patients with Sanfilippo …

BlackRock, Inc. Adds to Spruce Biosciences Inc (SPRB) Position -- Shares Look 1032% Overvalued on GF Value

BlackRock, Inc. recently increased its stake in Spruce Biosciences Inc (NASDAQ:SPRB) by 170,898 shares, investing approximately $1,008.96 at $54 per share. This move is notable given Spruce Biosciences' significant decline since its IPO and its current valuation, which GuruFocus identifies as 1032% overvalued based …

Spruce Biosciences names Jessica Cohen Pfeffer as VP of development

Spruce Biosciences, Inc. has appointed Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development. Dr. Cohen Pfeffer brings over a decade of biopharmaceutical industry experience, including her previous role as Executive Medical Director at BioMarin Pharmaceutical. Her appointment is effective immediately, and she was …

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Spruce Biosciences (NASDAQ:SPRB) has received a "Moderate Buy" consensus recommendation from eleven brokerages, with an average 12-month price target of $162.63. Despite several firms lowering their price targets recently, new coverage from B. Riley and Craig Hallum maintained buy ratings. The company reported a …

Grant of 13,000 RSUs to Spruce Biosciences (SPRB) Chief Medical Officer

Spruce Biosciences' Chief Medical Officer, Adrian W. Quartel, was granted 13,000 Restricted Stock Units (RSUs) on July 27, 2026. These RSUs, each representing one share of common stock, will vest 25% annually from 2027 through 2030, contingent on his continuous service. This grant aligns …

Spruce Biosciences (SPRB) gains 9.1% shareholder group led by AIGH

Spruce Biosciences (NASDAQ: SPRB) names Adrian Quartel as chief medical officer

Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as its new Chief Medical Officer, effective July 27, 2026. Dr. Quartel brings over 25 years of pharmaceutical experience, having previously served as CMO for several companies and spearheaded the launch of six rare …

Spruce Biosciences Inc (SPRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution